Law360, New York (November 08, 2011, 7:13 PM ET) -- Amylin Pharmaceuticals Inc. said Tuesday that it would pay Eli Lilly & Co. $250 million now and up to $1.2 billion later to end a lucrative diabetes drug joint marketing agreement that spurred contentious antitrust litigation between the two drugmakers.
San Diego-based Amylin — which teamed up with Indianapolis-based Eli Lilly in 2002 to develop a multimillion-dollar sales strategy to bring Type 2 diabetes drug Byetta, also known as exenatide, to market — alleged that Eli Lilly had violated the agreement when it announced earlier this...
Amylin, Lilly Wrap Up Diabetes Drug Alliance, Lawsuit
To view the full article, take a free trial now.
